The Trump administration’s December 2025 executive order directed expedited DEA rulemaking to move marijuana from Schedule I to Schedule III, producing a partial April 2026 order that immediately placed FDA-approved products and state-licensed medical cannabis into Schedule III. A new administrative hearing on broader rescheduling opened June 29 and closed July 15, 2026; post-hearing briefs are now due and an administrative law judge recommendation is expected late 2026 or early 2027, followed by further agency and possible judicial review. These procedural steps, rather than a final rule, currently anchor trader probabilities on full rescheduling timelines, with any acceleration or delay in the ALJ process or subsequent approvals serving as the main near-term catalysts.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato$796,389 Vol.
31 mar 2026
30 settembre
14%
31 dicembre
26%
$796,389 Vol.
30 settembre
$0 Vol.
14%
31 dicembre
$186,818 Vol.
26%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration’s December 2025 executive order directed expedited DEA rulemaking to move marijuana from Schedule I to Schedule III, producing a partial April 2026 order that immediately placed FDA-approved products and state-licensed medical cannabis into Schedule III. A new administrative hearing on broader rescheduling opened June 29 and closed July 15, 2026; post-hearing briefs are now due and an administrative law judge recommendation is expected late 2026 or early 2027, followed by further agency and possible judicial review. These procedural steps, rather than a final rule, currently anchor trader probabilities on full rescheduling timelines, with any acceleration or delay in the ALJ process or subsequent approvals serving as the main near-term catalysts.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Mercato aperto: Feb 7, 2026, 5:04 PM ET
Volume
$796,389Data di fine
31 mar 2026Mercato aperto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), between market creation and September 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by July 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The Trump administration’s December 2025 executive order directed expedited DEA rulemaking to move marijuana from Schedule I to Schedule III, producing a partial April 2026 order that immediately placed FDA-approved products and state-licensed medical cannabis into Schedule III. A new administrative hearing on broader rescheduling opened June 29 and closed July 15, 2026; post-hearing briefs are now due and an administrative law judge recommendation is expected late 2026 or early 2027, followed by further agency and possible judicial review. These procedural steps, rather than a final rule, currently anchor trader probabilities on full rescheduling timelines, with any acceleration or delay in the ALJ process or subsequent approvals serving as the main near-term catalysts.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Volume
$796,389Data di fine
31 mar 2026Mercato aperto
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The Trump administration’s December 2025 executive order directed expedited DEA rulemaking to move marijuana from Schedule I to Schedule III, producing a partial April 2026 order that immediately placed FDA-approved products and state-licensed medical cannabis into Schedule III. A new administrative hearing on broader rescheduling opened June 29 and closed July 15, 2026; post-hearing briefs are now due and an administrative law judge recommendation is expected late 2026 or early 2027, followed by further agency and possible judicial review. These procedural steps, rather than a final rule, currently anchor trader probabilities on full rescheduling timelines, with any acceleration or delay in the ALJ process or subsequent approvals serving as the main near-term catalysts.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti